Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure and chemical inhibition of the RET tyrosine kinase domain.

The Journal of biological chemistry - 3 Nov 2006

Knowles Phillip P, Murray-Rust Judith, Kjaer Svend, Scott Rizaldy P, Hanrahan Sarah, Santoro Massimo, Ibáñez Carlos F, McDonald Neil Q

Abstract excerpt

The RET proto-oncogene encodes a receptor tyrosine kinase for the glial cell line-derived neurotrophic factor family of ligands. Loss-of-function mutations in RET are implicated in Hirschsprung disease, whereas activating mutations in RET are found in human cancers, including familial medullar thyroid carcinoma and multiple endocrine neoplasias 2A and 2B. We report here the biochemical characterization of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crystallography, X-Ray
Share to Dimerization

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to Protein Structure, Quaternary

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-ret

Share to Recombinant Proteins

Share to Spodoptera

Source

Identifiers

PMID: 16928683
DOI: 10.1074/jbc.M605604200

Genes

RET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure and chemical inhibition of the RET tyrosine kinase domain.PMID 16928683Read ↗

Development of RET Kinase Inhibitors for Targeted Cancer TherapySemantic proximity Read ↗

State-of-the-Art Strategies for Targeting RET -Dependent CancersSemantic proximity Read ↗

Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Semantic proximity Read ↗

Progresses Toward Precision Medicine in RET-altered Solid Tumors.Semantic proximity Read ↗

Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBSSemantic proximity Read ↗

RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer.Semantic proximity Read ↗

Identification of a novel 5-amino-3-(5-cyclopropylisoxazol-3-yl)-1-isopropyl-1H-pyrazole-4-carboxamide as a specific RET kinase inhibitor.Semantic proximity Read ↗

RET kinase inhibitors: a review of recent patents (2012–2015)Semantic proximity Read ↗

Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Semantic proximity Read ↗

Identification of selective inhibitors of RET and comparison with current clinical candidates through development and validation of a robust screening cascadeSemantic proximity Read ↗

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase.Semantic proximity Read ↗

The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.